Trogenix closed a $95 million Series A to advance an AAV‑based platform (Odysseus) that uses synthetic super enhancers to activate therapeutic payloads selectively in cancer cells. The company plans a glioblastoma first‑in‑human study in early 2026 and pipeline expansion into colorectal metastases and other aggressive tumors. Investors highlighted the platform’s tumor‑restricted activation and dual payload design—local prodrug conversion plus immune cytokine stimulation—as a way to concentrate effect and limit systemic toxicity. The financing will fund IND‑enabling work and the upcoming clinical entry for its lead program.